Search

Your search keyword '"Hoogendoorn, Mels"' showing total 8 results
Start Over Author "Hoogendoorn, Mels" Journal haematologica
8 results on '"Hoogendoorn, Mels"'

3. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P., primary, van Oers, Marinus H.J., additional, van Norden, Yvette, additional, van der Straten, Lina, additional, Driessen, Julia, additional, Posthuma, Ward F.M., additional, Schipperus, Martin, additional, Chamuleau, Martine E.D., additional, Nijland, Marcel, additional, Doorduijn, Jeanette K., additional, Van Gelder, Michel, additional, Hoogendoorn, Mels, additional, De Croon, Francien, additional, Wittebol, Shulamiet, additional, Kerst, J. Martijn, additional, Marijt, Erik W.A., additional, Raymakers, Reinier A.P., additional, Schaafsma, Martijn R., additional, Dobber, Johan A., additional, Kersting, Sabina, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

5. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival

Author

Geelen, Inge G.P., primary, Thielen, Noortje, additional, Janssen, Jeroen J.W.M., additional, Hoogendoorn, Mels, additional, Roosma, Tanja J.A., additional, Willemsen, Sten P., additional, Valk, Peter J.M., additional, Visser, Otto, additional, Cornelissen, Jan J., additional, and Westerweel, Peter E., additional

Published
2017
Full Text
View/download PDF

7. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Author

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, and Levin MD

Subjects
Adolescent, Adult, Chlorambucil administration & dosage, Disease-Free Survival, Feasibility Studies, Female, Humans, Lenalidomide administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Rituximab administration & dosage, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2- and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34 ., (Copyright© 2019 Ferrata Storti Foundation.)

Published
2019
Full Text
View/download PDF

8. Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring.

Author

Altena R, van Roon E, Folkeringa R, de Wit H, and Hoogendoorn M

Subjects
Aged, Drug Incompatibility, Female, Humans, Morpholines administration & dosage, Morpholines adverse effects, Morpholines pharmacokinetics, Rivaroxaban, Thiophenes administration & dosage, Thiophenes adverse effects, Thiophenes pharmacokinetics, Antibiotics, Antitubercular administration & dosage, Antibiotics, Antitubercular adverse effects, Antibiotics, Antitubercular pharmacokinetics, Anticoagulants administration & dosage, Anticoagulants adverse effects, Anticoagulants pharmacokinetics, Atrial Fibrillation therapy, Ciprofloxacin administration & dosage, Ciprofloxacin adverse effects, Ciprofloxacin pharmacokinetics, Coronary Artery Bypass, Rifampin administration & dosage, Rifampin adverse effects, Rifampin pharmacokinetics
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results